We are live on ! Find out more
DSGN icon

Design Therapeutics
DSGN

95 hedge funds and large institutions have $206M invested in Design Therapeutics in 2024 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more call options, than puts

Call options by funds: $28K | Put options by funds: $16K

55% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 22

20% more capital invested

Capital invested by funds: $172M → $206M (+$34.1M)

2.52% more ownership

Funds ownership: 56.57% → 59.1% (+2.5%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less funds holding

Funds holding: 100 → 95 (-5)

17% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 18

Holders
95
Holders Change
-5
Holders Change %
-5%
% of All Funds
1.25%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
15
Increased
34
Reduced
22
Closed
18
Calls
$28K
Puts
$16K
Net Calls
+$12K
Net Calls Change
+$169K

Top Buyers

1
DCM
Driehaus Capital Management
Illinois
+$4.49M
2
MB
MPM BioImpact
Massachusetts
+$3.24M
3
Citadel Advisors
Citadel Advisors
Florida
+$2.22M
4
EC
EcoR1 Capital
California
+$2.16M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.48M

Top Sellers

1
PGCM
Prescott Group Capital Management
Oklahoma
-$1.85M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.68M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$1.52M
4
Millennium Management
Millennium Management
New York
-$1.12M
5
BCM
Bridgeway Capital Management
Texas
-$621K
Name Holding Trade Value Shares
Change 		Change in
Stake
SOCM
1
SR One Capital Management
Pennsylvania
$40.3M – – –
LGM
2
Logos Global Management
California
$26M – – –
BlackRock
3
BlackRock
New York
$15.9M +$1.28M +220,802 +9%
FLSM
4
Frazier Life Sciences Management
California
$12.1M +$353K +61,000 +3%
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$11.5M +$1.48M +256,010 +16%
BBA
6
Baker Bros. Advisors
New York
$10.8M – – –
TCM
7
Tang Capital Management
California
$9.14M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$8.83M +$213K +36,721 +3%
AC
9
Almitas Capital
California
$8.17M – – –
Citadel Advisors
10
Citadel Advisors
Florida
$5.92M +$2.22M +383,243 +67%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$5.87M +$713K +123,217 +15%
DCM
12
Driehaus Capital Management
Illinois
$4.79M +$4.49M +776,082 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$4.7M +$17.9K +3,090 +0.4%
State Street
14
State Street
Massachusetts
$4.46M +$188K +32,493 +5%
Acadian Asset Management
15
Acadian Asset Management
Massachusetts
$3.5M -$90K -15,556 -3%
MB
16
MPM BioImpact
Massachusetts
$3.45M +$3.24M +559,547 New
D.E. Shaw & Co
17
D.E. Shaw & Co
New York
$3.16M -$408K -70,528 -12%
EC
18
EcoR1 Capital
California
$2.63M +$2.16M +372,849 +693%
Northern Trust
19
Northern Trust
Illinois
$2.39M +$297K +51,351 +15%
Morgan Stanley
20
Morgan Stanley
New York
$2.14M -$478K -82,615 -19%
Goldman Sachs
21
Goldman Sachs
New York
$1.83M +$125K +21,597 +8%
Charles Schwab
22
Charles Schwab
California
$1.63M +$41.9K +7,243 +3%
Renaissance Technologies
23
Renaissance Technologies
New York
$1.56M -$119K -20,500 -7%
Two Sigma Advisers
24
Two Sigma Advisers
New York
$1.44M -$411K -71,000 -23%
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$1.33M +$468K +80,905 +60%
1
2 3 4 5

DSGN Hedge Fund Activity: Q4 2024 in Review

95 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q4 2024, worth a combined $206M — up 20% from $172M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of DSGN and 15 opened new positions — a net loss of 3 holders — while 22 trimmed existing stakes and 34 added.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $4.49M. The largest seller was Prescott Group Capital Management, exiting entirely with an estimated $1.85M sold.

  • 95 institutional investors held Design Therapeutics (DSGN) as of Q4 2024, down from 100 in Q3 2024.
  • Funds reported $206M of Design Therapeutics stock for Q4 2024, up 20% quarter-over-quarter.
  • 15 funds opened new Design Therapeutics positions in Q4 2024 and 18 closed out, a net change of -3 holders.
  • The largest Design Therapeutics buyer in Q4 2024 was Driehaus Capital Management, an estimated $4.49M added.
  • The largest Design Therapeutics seller in Q4 2024 was Prescott Group Capital Management, an estimated $1.85M sold.

Based on aggregated 13F filings for Q4 2024.